Dacliximab
| Dacliximab | |
|---|---|
| Term | Dacliximab |
| Short definition | Dacliximab - (pronounced) (duh-KLIK-sih-mab) A drug used to stop the body from rejecting kidney transplants. It is also being studied in the treatment of some cancers and other conditions. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Dacliximab - (pronounced) (duh-KLIK-sih-mab) A drug used to stop the body from rejecting kidney transplants. It is also being studied in the treatment of some cancers and other conditions. Dacliximab attaches to receptors for a protein called interleukin-2 found on some types of immune cells and cancer cells. This can help suppress the body's immune response and kill cancer cells. Dacliximab is a type of monoclonal antibody. Also called daclizumab and zenapax
External links
- Medical encyclopedia article on Dacliximab
- Wikipedia's article - Dacliximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski